Dare Bioscience Inc (DARE)

[nonsequetor]

Main catalyst coming soon: FDA approval of NDE for Ovaprene, non hormonal birth control product. The company already in partnership with Bayer and NIH on this.
$1B
market. NDE approval will trigger the start of a pivotal Ph3 trial this year. Hopefully, their second FDA-approved product by next year. The trial will only cost them $5, and they get a bonus check from Bayer
$20M
on start.

Other pipeline catalysts soon:
1)Xaciato marketing/sales/revenue by Q4 or earlier.
2) VVA-1 Ph2 data: Q3
3) Sildenafil Ph2 data: Q3